Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer had made "significant progress" toward regaining FDA compliance, while the Company had never verified that claim through its own inspection of the facility
- Fox News Network, LLCFOX NEWS BOOKS SET TO PUBLISH SEQUEL BY DR. MARC SIEGEL ENTITLED "THE ANGELS AMONG US"New Book Follows Siegel's #1 New York Times Bestseller "The Miracles Among Us" — FOX News Books author and FOX News Channel senior medical analyst Dr. Marc Siegel returns with his latest book, "The Angels Among Us: How God's Messengers Play a Role in...
- Mexico Wellness Tourism Market Outlook Report 2026-2034: Rising Demand for Holistic Retreats, Medical Spas and Luxury Experiences Creates New Growth Opportunities"Mexico Wellness Tourism Market Size and Share Analysis Report: Forecast Trends and Outlook (2025-2034)" has been added to ResearchAndMarkets.com's offering.
- Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesityPress release – No. 17 / 2026
- Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin SyndromeAshburn, Virginia, September 22nd, 2026, FinanceWire – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need – Follows July 2026 FDA Clearance of the … Continue reading "Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome"
- Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug PathwaysEndovia financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines
- Teal HealthTeal Health Raises $22 Million Series A to Expand Access to the Most Accurate FDA-Authorized At-Home HPV Cervical Cancer ScreeningRound Led by .406 Ventures Fuels Teal Health's Next Phase of Growth, Expanding Payor, Health System, Employer and Provider Partnerships Ahead of Broad Insurance Coverage in 2027 Teal Health , creators of the Teal Wand™, the first and most accurate FDA-authorized self-collection device for at-home HPV cervical cancer screening, today announced $22 million in Series A funding to meet accelerating cons
- OracleOracle PartnerNetwork Expands Incentives to Help Partners Accelerate Healthcare TransformationCompanies: Oracle CorporationOracle Health and Life Sciences Summit – Orlando, FL—Sep 22, 2026 Oracle today announced an expansion of its Oracle PartnerNetwork (OPN) incentives to include Oracle Health and Life Sciences . The expansion creates a more consistent partner experience across Oracle Health and Life Sciences, Oracle Cloud Infrastructure (OCI) , Oracle Fusion Cloud Applications , and other eligible Oracle cloud offerings. The new benefi
- RVO Health, LLCAIQ by Fullspan Health Gives Pharma Marketers a Way to Measure and Improve Visibility in AI SearchAIQ analysis finds Fullspan Health's content appearing in up to 81% of AI citations for key condition questions, and as much as 3.6x more often than competitors across ChatGPT, Claude and Gemini — Fullspan Health™, a unified B2B healthcare platform...
- Cold Chain Expansion Fuels Mexico Refrigerated Transport Market, Set to Reach US$545.25 Million by 2034 at 4.22% CAGRCold-chain demand is rising across food, pharma and cross-border trade, creating opportunities in smart monitoring, multi-temperature fleets and energy-efficient refrigeration
- Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee SystemSmith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK Total Knee System.
- PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients